Key Takeaways Agios reported a Q3 loss of $1.78 per share, beating expectations of a loss of$1.93.AGIO's total revenues climbed 44% year over year to $12.9 million, fueled by Pyrukynd sales.The FDA decision on Pyrukynd's thalassemia indication is due on Dec. 7, as the EMA gives a positive opinion.Agios Pharmaceuticals (AGIO) incurred a loss of$1.78 per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.93. In the year-ago quarter, the company had reported earnin ...